Hepatitis A Antibody, IgM

Also known as: Anti-HAV, IgM, Antibody to Hepatitis A Virus, IgM, HAVAb, IgM

Clinical Use

Use

This assay is intended for use as an aid in the diagnosis of acute or recent infection (usually 6 months or less) with hepatitis A virus (HAV). This is an in vitro diagnostic immunoassay for the qualitative determination of IgM response to HAV. The presence of IgM antibody to HAV is diagnostic of acute HAV infection. To reduce false-positive tests, persons should only be tested for IgM anti-HAV if they are symptomatic and suspected of having HAV infection.

Special Instructions

Not provided.

Limitations

This assay is not cleared by the FDA for screening of blood or plasma donors. Performance characteristics are not established for immunocompromised or immunosuppressed patients, cord blood, patients under 2 years old, or cadaveric specimens. Anti-HAV tests might be positive after hepatitis A vaccination, but are usually not sensitive enough to detect low protective antibody levels post-vaccination.

Test Details

Methodology

Immunoassay (CLIA)

Biomarkers

IgM antibody to HAV

Protein

Other

Other • Binary (Detected / Not Detected)

LOINC Codes

Order Codes

13950-1 - HAV IgM SerPl Ql IA

Result Codes

13950-1 - HAV IgM SerPl Ql IA

Result Turnaround Time

1-2 days

Specimen

Serum

Volume

1 mL

Minimum Volume

0.4 mL

Container

Gel-barrier tube or serum transfer tube

Collection Instructions

Centrifuge sample within 24 hours of collection. If a gel-barrier tube is not used, or if the sample will be shipped frozen, transfer separated serum to a screw-cap polypropylene transport tube. Do not freeze gel-barrier tube (pour off serum first).